Acumen Pharmaceuticals, Inc. (ABOS) Stock Forecast
ABOS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 6 analysts
- Price target
- $7.60 average of analyst targets
- Upside to target
- +349.7% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.43
- 52-week range
- $1.55 – $3.37
ABOS analyst ratings
6 analystsNumber of analysts at each rating.
ABOS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ABOS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.39 | −$0.49 | −$0.24 | −$0.44 | +10.3% | 3 |
| Current fiscal year (2026) | −$1.62 | −$1.88 | −$1.27 | −$2.00 | +19.0% | 3 |
| Next fiscal year (2027) | −$1.43 | −$1.47 | −$1.37 | −$1.62 | +11.5% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ABOS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
ABOS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ABOS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.42 | −$0.38 | −$0.38 | −$0.38 | −$0.39 | −6.8% | 1 up · 1 down |
| Current fiscal year (2026) | −$1.58 | −$1.59 | −$1.59 | −$1.59 | −$1.62 | +2.3% | 1 up · 2 down |
| Next fiscal year (2027) | −$1.51 | −$1.43 | −$1.43 | −$1.43 | −$1.43 | −4.8% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ABOS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ABOS beat in 5 of 12.
What analysts expect from ABOS
6 analysts cover Acumen Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.60, 349.7% above the latest close of $1.69. Analysts expect earnings of −$1.62 per share for 2026, +19.0% from a year earlier. For 2027 the average estimate is −$1.43 per share. Acumen Pharmaceuticals beat the EPS estimate in 5 of the last 12 quarters.
Related: ABOS income statement, ABOS key metrics, ABOS chart. See the ABOS stock overview for the latest quote and news.
ABOS forecast FAQ
What is Acumen Pharmaceuticals's price target?
The average analyst price target for Acumen Pharmaceuticals is $7.60, 349.7% above the latest close of $1.69.
Is Acumen Pharmaceuticals a buy, hold or sell?
Of 6 analysts covering Acumen Pharmaceuticals, 6 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Acumen Pharmaceuticals's EPS forecast?
Analysts forecast −$1.62 per share for 2026 (range −$1.88 to −$1.27); for 2027 the estimate is −$1.43.
When does Acumen Pharmaceuticals report earnings?
Acumen Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens; the EPS estimate is $-0.43.
Does Acumen Pharmaceuticals usually beat earnings estimates?
Acumen Pharmaceuticals reported EPS at or above the analyst estimate in 5 of the last 12 quarters.